| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dementia | 15 | 2021 | 453 | 2.700 |
Why?
|
| Comparative Effectiveness Research | 5 | 2012 | 126 | 1.480 |
Why?
|
| Hypertension | 10 | 2023 | 1503 | 1.400 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 2023 | 257 | 1.340 |
Why?
|
| Medicare | 18 | 2023 | 860 | 1.320 |
Why?
|
| Heart Failure | 17 | 2016 | 2516 | 1.150 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 6 | 2022 | 849 | 1.120 |
Why?
|
| United States | 65 | 2023 | 15433 | 1.100 |
Why?
|
| United States Department of Veterans Affairs | 10 | 2012 | 605 | 1.060 |
Why?
|
| Antipsychotic Agents | 12 | 2021 | 414 | 1.050 |
Why?
|
| Angiotensin Receptor Antagonists | 5 | 2023 | 151 | 1.020 |
Why?
|
| Cholinergic Antagonists | 7 | 2019 | 58 | 0.970 |
Why?
|
| Retrospective Studies | 67 | 2023 | 37905 | 0.930 |
Why?
|
| Prescription Drugs | 5 | 2019 | 64 | 0.920 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2018 | 1303 | 0.910 |
Why?
|
| Risk | 14 | 2017 | 1972 | 0.890 |
Why?
|
| Antihypertensive Agents | 5 | 2012 | 395 | 0.890 |
Why?
|
| Diabetes Mellitus | 13 | 2023 | 1054 | 0.840 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2022 | 1362 | 0.830 |
Why?
|
| Economics, Pharmaceutical | 3 | 2009 | 13 | 0.810 |
Why?
|
| Hospitals, Veterans | 17 | 2007 | 397 | 0.780 |
Why?
|
| Aged | 85 | 2023 | 70117 | 0.780 |
Why?
|
| Urinary Bladder, Overactive | 4 | 2021 | 37 | 0.740 |
Why?
|
| Hyperlipidemias | 4 | 2022 | 235 | 0.740 |
Why?
|
| Depression | 12 | 2020 | 1715 | 0.710 |
Why?
|
| Selection Bias | 2 | 2009 | 50 | 0.710 |
Why?
|
| Nursing Homes | 11 | 2019 | 99 | 0.700 |
Why?
|
| Comorbidity | 16 | 2020 | 2352 | 0.700 |
Why?
|
| Proportional Hazards Models | 11 | 2019 | 4988 | 0.690 |
Why?
|
| Cardiovascular Diseases | 6 | 2023 | 2195 | 0.670 |
Why?
|
| Dyslipidemias | 2 | 2015 | 235 | 0.650 |
Why?
|
| Metformin | 1 | 2022 | 378 | 0.650 |
Why?
|
| Risk Adjustment | 5 | 2015 | 83 | 0.640 |
Why?
|
| Databases, Factual | 10 | 2023 | 2218 | 0.630 |
Why?
|
| Medicare Part C | 5 | 2023 | 31 | 0.610 |
Why?
|
| Motivational Interviewing | 3 | 2023 | 49 | 0.610 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2023 | 4757 | 0.600 |
Why?
|
| Medicare Part D | 4 | 2020 | 30 | 0.590 |
Why?
|
| Epidemiologic Research Design | 1 | 2016 | 11 | 0.570 |
Why?
|
| Cohort Studies | 28 | 2022 | 9244 | 0.570 |
Why?
|
| Paroxetine | 4 | 2017 | 34 | 0.570 |
Why?
|
| Proton Pump Inhibitors | 1 | 2019 | 249 | 0.550 |
Why?
|
| Veterans | 11 | 2011 | 1641 | 0.540 |
Why?
|
| Gastroesophageal Reflux | 1 | 2019 | 334 | 0.540 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 15694 | 0.510 |
Why?
|
| Female | 82 | 2023 | 141928 | 0.500 |
Why?
|
| Risk Assessment | 8 | 2016 | 6869 | 0.490 |
Why?
|
| Humans | 116 | 2023 | 261506 | 0.480 |
Why?
|
| Odds Ratio | 5 | 2016 | 2316 | 0.460 |
Why?
|
| Drug Utilization Review | 3 | 2019 | 36 | 0.460 |
Why?
|
| Male | 79 | 2023 | 123000 | 0.450 |
Why?
|
| Managed Care Programs | 3 | 2022 | 74 | 0.440 |
Why?
|
| Longitudinal Studies | 7 | 2021 | 1945 | 0.430 |
Why?
|
| Anti-Obesity Agents | 1 | 2012 | 30 | 0.420 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2023 | 198 | 0.410 |
Why?
|
| Antirheumatic Agents | 2 | 2023 | 167 | 0.400 |
Why?
|
| Losartan | 1 | 2011 | 46 | 0.400 |
Why?
|
| Aged, 80 and over | 32 | 2020 | 29902 | 0.400 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2019 | 1756 | 0.390 |
Why?
|
| Valine | 1 | 2011 | 176 | 0.380 |
Why?
|
| Tetrazoles | 1 | 2011 | 106 | 0.380 |
Why?
|
| Multivariate Analysis | 14 | 2016 | 4298 | 0.380 |
Why?
|
| Logistic Models | 16 | 2017 | 3441 | 0.380 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 194 | 0.360 |
Why?
|
| Aortic Aneurysm, Abdominal | 4 | 2007 | 384 | 0.360 |
Why?
|
| Insurance, Pharmaceutical Services | 1 | 2009 | 13 | 0.360 |
Why?
|
| Medication Adherence | 6 | 2023 | 492 | 0.360 |
Why?
|
| Angioplasty | 2 | 2007 | 94 | 0.350 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2023 | 410 | 0.340 |
Why?
|
| Pharmaceutical Services | 1 | 2009 | 34 | 0.340 |
Why?
|
| Receptor, ErbB-2 | 3 | 2023 | 2518 | 0.330 |
Why?
|
| Baths | 2 | 2020 | 16 | 0.330 |
Why?
|
| Multiple Sclerosis | 2 | 2023 | 349 | 0.330 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 383 | 0.330 |
Why?
|
| Quality Indicators, Health Care | 3 | 2019 | 348 | 0.330 |
Why?
|
| Pneumonia | 3 | 2020 | 751 | 0.320 |
Why?
|
| Benzimidazoles | 1 | 2011 | 428 | 0.320 |
Why?
|
| Case-Control Studies | 14 | 2023 | 6100 | 0.310 |
Why?
|
| Elective Surgical Procedures | 3 | 2007 | 250 | 0.310 |
Why?
|
| Middle Aged | 48 | 2023 | 86204 | 0.310 |
Why?
|
| Prescription Drug Monitoring Programs | 2 | 2017 | 11 | 0.310 |
Why?
|
| Data Interpretation, Statistical | 4 | 2011 | 482 | 0.300 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2020 | 121 | 0.300 |
Why?
|
| Research | 3 | 2023 | 415 | 0.300 |
Why?
|
| Diuretics | 2 | 2005 | 170 | 0.300 |
Why?
|
| Accidental Falls | 3 | 2016 | 142 | 0.300 |
Why?
|
| Leptospirosis | 1 | 2006 | 3 | 0.300 |
Why?
|
| Drug Utilization | 3 | 2020 | 179 | 0.300 |
Why?
|
| Cholinesterase Inhibitors | 3 | 2022 | 110 | 0.290 |
Why?
|
| Risk Factors | 23 | 2017 | 17523 | 0.290 |
Why?
|
| Health Expenditures | 3 | 2018 | 211 | 0.290 |
Why?
|
| Propensity Score | 7 | 2017 | 750 | 0.290 |
Why?
|
| Incidence | 15 | 2019 | 5673 | 0.280 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 598 | 0.280 |
Why?
|
| Dog Diseases | 1 | 2006 | 73 | 0.280 |
Why?
|
| Fractures, Bone | 3 | 2016 | 291 | 0.280 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2016 | 56 | 0.270 |
Why?
|
| Varenicline | 2 | 2016 | 65 | 0.270 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 521 | 0.270 |
Why?
|
| Bupropion | 2 | 2016 | 76 | 0.260 |
Why?
|
| Ethical Review | 1 | 2005 | 5 | 0.260 |
Why?
|
| Data Collection | 3 | 2016 | 620 | 0.260 |
Why?
|
| Quality of Health Care | 5 | 2005 | 621 | 0.260 |
Why?
|
| Inappropriate Prescribing | 2 | 2015 | 50 | 0.260 |
Why?
|
| Ethics Committees, Research | 1 | 2005 | 40 | 0.260 |
Why?
|
| Diabetic Angiopathies | 1 | 2005 | 78 | 0.260 |
Why?
|
| Fingolimod Hydrochloride | 2 | 2023 | 45 | 0.250 |
Why?
|
| Human Experimentation | 1 | 2005 | 51 | 0.250 |
Why?
|
| Hospitalization | 10 | 2012 | 2083 | 0.250 |
Why?
|
| Alzheimer Disease | 3 | 2022 | 855 | 0.250 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2017 | 598 | 0.240 |
Why?
|
| Internationality | 3 | 2009 | 208 | 0.240 |
Why?
|
| Homes for the Aged | 4 | 2017 | 24 | 0.240 |
Why?
|
| Polypharmacy | 3 | 2019 | 57 | 0.240 |
Why?
|
| Drug Prescriptions | 3 | 2019 | 289 | 0.230 |
Why?
|
| Workload | 1 | 2005 | 198 | 0.230 |
Why?
|
| Cross Infection | 2 | 2020 | 544 | 0.230 |
Why?
|
| Obesity | 2 | 2015 | 2884 | 0.230 |
Why?
|
| Psychotic Disorders | 3 | 2010 | 147 | 0.230 |
Why?
|
| Outpatients | 1 | 2006 | 462 | 0.230 |
Why?
|
| Cognitive Dysfunction | 2 | 2019 | 333 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2010 | 830 | 0.220 |
Why?
|
| Parkinson Disease | 2 | 2020 | 708 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2023 | 129 | 0.210 |
Why?
|
| Surgery Department, Hospital | 1 | 2002 | 30 | 0.210 |
Why?
|
| Benzodiazepines | 4 | 2017 | 170 | 0.200 |
Why?
|
| Medication Errors | 2 | 2015 | 174 | 0.200 |
Why?
|
| Treatment Outcome | 12 | 2023 | 32848 | 0.200 |
Why?
|
| Hospital Mortality | 3 | 2015 | 1274 | 0.190 |
Why?
|
| Survival Rate | 5 | 2023 | 12221 | 0.190 |
Why?
|
| Postmenopause | 1 | 2022 | 378 | 0.190 |
Why?
|
| Cross-Sectional Studies | 9 | 2020 | 4314 | 0.190 |
Why?
|
| Muscarinic Antagonists | 4 | 2021 | 83 | 0.190 |
Why?
|
| Health Maintenance Organizations | 3 | 2009 | 29 | 0.190 |
Why?
|
| Decision Making | 4 | 2009 | 1287 | 0.180 |
Why?
|
| Chlorhexidine | 2 | 2020 | 88 | 0.180 |
Why?
|
| Analgesics, Opioid | 3 | 2019 | 1371 | 0.180 |
Why?
|
| Smoking Cessation | 2 | 2016 | 712 | 0.180 |
Why?
|
| Biological Products | 1 | 2023 | 274 | 0.180 |
Why?
|
| Depressive Disorder | 3 | 2015 | 557 | 0.180 |
Why?
|
| Health Status | 3 | 2016 | 590 | 0.180 |
Why?
|
| Intensive Care Units | 4 | 2020 | 717 | 0.170 |
Why?
|
| Cognition | 2 | 2015 | 968 | 0.170 |
Why?
|
| Psychotropic Drugs | 2 | 2019 | 133 | 0.170 |
Why?
|
| Advisory Committees | 2 | 2011 | 203 | 0.170 |
Why?
|
| Deprescriptions | 1 | 2019 | 24 | 0.170 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2019 | 56 | 0.170 |
Why?
|
| Lipids | 1 | 2022 | 644 | 0.160 |
Why?
|
| Chronic Disease | 2 | 2016 | 1819 | 0.160 |
Why?
|
| Electronic Health Records | 2 | 2020 | 929 | 0.160 |
Why?
|
| Patient Readmission | 4 | 2016 | 548 | 0.160 |
Why?
|
| Peptic Ulcer | 1 | 2019 | 140 | 0.160 |
Why?
|
| Decision Support Techniques | 2 | 2016 | 622 | 0.160 |
Why?
|
| Information Storage and Retrieval | 1 | 2019 | 135 | 0.160 |
Why?
|
| Prescription Drug Misuse | 1 | 2017 | 11 | 0.160 |
Why?
|
| Drug Industry | 1 | 2018 | 88 | 0.160 |
Why?
|
| SEER Program | 2 | 2019 | 1000 | 0.150 |
Why?
|
| Controlled Substances | 1 | 2017 | 15 | 0.150 |
Why?
|
| Adult | 27 | 2023 | 77950 | 0.150 |
Why?
|
| Health Services Research | 3 | 2002 | 233 | 0.150 |
Why?
|
| Health Care Costs | 1 | 2003 | 674 | 0.150 |
Why?
|
| Diabetes Complications | 4 | 2010 | 305 | 0.150 |
Why?
|
| Drug Interactions | 1 | 2019 | 553 | 0.150 |
Why?
|
| Patient Discharge Summaries | 1 | 2016 | 9 | 0.150 |
Why?
|
| Medicaid | 3 | 2019 | 279 | 0.140 |
Why?
|
| Drug Costs | 1 | 2018 | 144 | 0.140 |
Why?
|
| Coronary Artery Bypass | 1 | 2002 | 708 | 0.140 |
Why?
|
| Health Policy | 2 | 2009 | 291 | 0.140 |
Why?
|
| Patient Discharge | 4 | 2016 | 661 | 0.140 |
Why?
|
| Medication Therapy Management | 1 | 2016 | 36 | 0.140 |
Why?
|
| Drug Therapy, Combination | 4 | 2023 | 2315 | 0.140 |
Why?
|
| Neoplasms | 2 | 2020 | 15193 | 0.140 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 46 | 0.140 |
Why?
|
| Critical Care | 2 | 2020 | 770 | 0.130 |
Why?
|
| Southeastern United States | 2 | 2006 | 54 | 0.130 |
Why?
|
| Texas | 7 | 2023 | 6311 | 0.130 |
Why?
|
| Hip Fractures | 1 | 2016 | 76 | 0.130 |
Why?
|
| Health Services Administration | 2 | 2005 | 13 | 0.130 |
Why?
|
| Diagnosis-Related Groups | 1 | 1995 | 25 | 0.130 |
Why?
|
| Models, Statistical | 3 | 2015 | 1171 | 0.130 |
Why?
|
| Hospital Information Systems | 1 | 1995 | 46 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 2992 | 0.130 |
Why?
|
| Nicotinic Agonists | 1 | 2015 | 113 | 0.130 |
Why?
|
| Emergency Service, Hospital | 3 | 2019 | 1148 | 0.130 |
Why?
|
| Regression Analysis | 2 | 2009 | 1546 | 0.120 |
Why?
|
| Colistin | 1 | 2014 | 33 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2023 | 15862 | 0.120 |
Why?
|
| Residence Characteristics | 3 | 2012 | 348 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2023 | 6207 | 0.120 |
Why?
|
| Lung Diseases, Obstructive | 7 | 1999 | 46 | 0.120 |
Why?
|
| Causality | 2 | 2015 | 178 | 0.120 |
Why?
|
| Health Services Needs and Demand | 2 | 2015 | 244 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 799 | 0.120 |
Why?
|
| Tobacco Use Disorder | 1 | 2016 | 284 | 0.120 |
Why?
|
| Methotrexate | 3 | 2023 | 999 | 0.120 |
Why?
|
| Age Factors | 6 | 2015 | 5377 | 0.120 |
Why?
|
| Health Resources | 1 | 1995 | 168 | 0.120 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 285 | 0.120 |
Why?
|
| Anxiety Disorders | 2 | 2009 | 666 | 0.110 |
Why?
|
| Dementia, Vascular | 2 | 2010 | 16 | 0.110 |
Why?
|
| Health Personnel | 1 | 2019 | 625 | 0.110 |
Why?
|
| Physicians | 2 | 2019 | 882 | 0.110 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2014 | 158 | 0.110 |
Why?
|
| Observation | 2 | 2010 | 48 | 0.110 |
Why?
|
| Health Care Surveys | 2 | 2012 | 430 | 0.110 |
Why?
|
| HIV Seroprevalence | 1 | 1992 | 11 | 0.110 |
Why?
|
| Central Nervous System Stimulants | 1 | 2014 | 225 | 0.110 |
Why?
|
| Mental Disorders | 2 | 2019 | 862 | 0.110 |
Why?
|
| Prospective Studies | 9 | 2019 | 12873 | 0.110 |
Why?
|
| Sterilization, Tubal | 1 | 1992 | 17 | 0.110 |
Why?
|
| California | 3 | 2006 | 208 | 0.110 |
Why?
|
| Socioeconomic Factors | 3 | 2015 | 1225 | 0.110 |
Why?
|
| Weight Gain | 1 | 2016 | 464 | 0.110 |
Why?
|
| Prevalence | 5 | 2017 | 3260 | 0.110 |
Why?
|
| Mortality | 1 | 2015 | 343 | 0.110 |
Why?
|
| Substance-Related Disorders | 1 | 2017 | 524 | 0.110 |
Why?
|
| Galantamine | 2 | 2022 | 11 | 0.110 |
Why?
|
| Rivastigmine | 2 | 2022 | 26 | 0.110 |
Why?
|
| Housing | 1 | 2012 | 61 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 651 | 0.110 |
Why?
|
| Nonlinear Dynamics | 1 | 2012 | 78 | 0.100 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 715 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2009 | 1085 | 0.100 |
Why?
|
| Phenylcarbamates | 2 | 2022 | 25 | 0.100 |
Why?
|
| Models, Structural | 1 | 2011 | 103 | 0.100 |
Why?
|
| Fosinopril | 1 | 2011 | 5 | 0.100 |
Why?
|
| Valsartan | 1 | 2011 | 38 | 0.100 |
Why?
|
| Lisinopril | 1 | 2011 | 24 | 0.100 |
Why?
|
| Enalapril | 1 | 2011 | 20 | 0.100 |
Why?
|
| Captopril | 1 | 2011 | 34 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2012 | 217 | 0.100 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2014 | 274 | 0.100 |
Why?
|
| Hospitals | 1 | 1995 | 485 | 0.100 |
Why?
|
| Medication Systems, Hospital | 1 | 2011 | 38 | 0.100 |
Why?
|
| Indans | 2 | 2022 | 68 | 0.100 |
Why?
|
| Drug Therapy | 2 | 2010 | 205 | 0.100 |
Why?
|
| Pandemics | 1 | 2020 | 1559 | 0.100 |
Why?
|
| Research Design | 2 | 2011 | 1544 | 0.090 |
Why?
|
| Nurses | 1 | 2011 | 80 | 0.090 |
Why?
|
| Sex Factors | 2 | 2015 | 2139 | 0.090 |
Why?
|
| Leg | 2 | 2002 | 226 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 156 | 0.090 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2011 | 233 | 0.090 |
Why?
|
| Fee-for-Service Plans | 1 | 2009 | 40 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 1 | 2010 | 142 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 3 | 2007 | 585 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2009 | 254 | 0.090 |
Why?
|
| Poverty | 1 | 1992 | 471 | 0.080 |
Why?
|
| Sick Role | 1 | 2009 | 64 | 0.080 |
Why?
|
| Adolescent | 11 | 2023 | 31252 | 0.080 |
Why?
|
| Somatoform Disorders | 1 | 2009 | 61 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 2 | 2007 | 655 | 0.080 |
Why?
|
| Reproducibility of Results | 4 | 2016 | 6009 | 0.080 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2011 | 412 | 0.080 |
Why?
|
| Palliative Care | 1 | 2019 | 2037 | 0.080 |
Why?
|
| Quetiapine Fumarate | 3 | 2012 | 16 | 0.070 |
Why?
|
| Dibenzothiazepines | 3 | 2012 | 13 | 0.070 |
Why?
|
| Iatrogenic Disease | 2 | 1999 | 183 | 0.070 |
Why?
|
| Insurance Coverage | 1 | 2009 | 256 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 4892 | 0.070 |
Why?
|
| Cost of Illness | 1 | 2010 | 498 | 0.070 |
Why?
|
| Demography | 2 | 2006 | 435 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2021 | 1544 | 0.070 |
Why?
|
| Risperidone | 3 | 2012 | 62 | 0.070 |
Why?
|
| Smoking | 1 | 2015 | 2440 | 0.070 |
Why?
|
| ROC Curve | 1 | 2009 | 1183 | 0.070 |
Why?
|
| Piperidines | 2 | 2022 | 1035 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2023 | 1375 | 0.070 |
Why?
|
| Bacteremia | 1 | 2011 | 689 | 0.070 |
Why?
|
| Myocardial Ischemia | 1 | 2009 | 435 | 0.070 |
Why?
|
| Environment | 1 | 2006 | 190 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 200 | 0.070 |
Why?
|
| Kidney | 1 | 2014 | 2146 | 0.070 |
Why?
|
| Ambulatory Care | 1 | 2009 | 554 | 0.070 |
Why?
|
| Oklahoma | 1 | 2004 | 9 | 0.070 |
Why?
|
| Dogs | 1 | 2006 | 1155 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2005 | 418 | 0.060 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 208 | 0.060 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 14889 | 0.060 |
Why?
|
| Hypolipidemic Agents | 1 | 2006 | 190 | 0.060 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2011 | 595 | 0.060 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2005 | 220 | 0.060 |
Why?
|
| Crotonates | 1 | 2023 | 5 | 0.060 |
Why?
|
| Dimethyl Fumarate | 1 | 2023 | 10 | 0.060 |
Why?
|
| Potassium Deficiency | 1 | 2003 | 12 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2005 | 497 | 0.060 |
Why?
|
| Netherlands | 1 | 2003 | 83 | 0.060 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2010 | 1021 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 672 | 0.060 |
Why?
|
| Delivery of Health Care | 1 | 2010 | 860 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2009 | 787 | 0.050 |
Why?
|
| Policy Making | 1 | 2003 | 85 | 0.050 |
Why?
|
| Amputation | 1 | 2001 | 1 | 0.050 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2005 | 422 | 0.050 |
Why?
|
| Quality of Life | 1 | 2016 | 4532 | 0.050 |
Why?
|
| Pressure Ulcer | 1 | 2003 | 106 | 0.050 |
Why?
|
| Time Factors | 5 | 2016 | 12926 | 0.050 |
Why?
|
| Tolterodine Tartrate | 1 | 2021 | 3 | 0.050 |
Why?
|
| Acetylcholinesterase | 1 | 2021 | 23 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2009 | 2594 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2005 | 383 | 0.050 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2002 | 160 | 0.050 |
Why?
|
| Young Adult | 5 | 2019 | 21445 | 0.050 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 32 | 0.050 |
Why?
|
| Soaps | 1 | 2020 | 7 | 0.050 |
Why?
|
| Injections | 1 | 2021 | 285 | 0.050 |
Why?
|
| Linear Models | 3 | 2016 | 1085 | 0.050 |
Why?
|
| Azithromycin | 1 | 2020 | 78 | 0.050 |
Why?
|
| HIV Infections | 1 | 1992 | 2134 | 0.040 |
Why?
|
| Forecasting | 1 | 2003 | 694 | 0.040 |
Why?
|
| Benchmarking | 1 | 2002 | 273 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2023 | 629 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2001 | 246 | 0.040 |
Why?
|
| Brain | 1 | 2012 | 4113 | 0.040 |
Why?
|
| Survival Analysis | 3 | 2009 | 9180 | 0.040 |
Why?
|
| Telephone | 1 | 2019 | 163 | 0.040 |
Why?
|
| Students, Pharmacy | 1 | 2019 | 54 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2003 | 945 | 0.040 |
Why?
|
| Cholesterol, LDL | 1 | 2022 | 565 | 0.040 |
Why?
|
| Gift Giving | 1 | 2018 | 25 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 4320 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 586 | 0.040 |
Why?
|
| Conflict of Interest | 1 | 2018 | 98 | 0.040 |
Why?
|
| Analysis of Variance | 3 | 2011 | 2307 | 0.040 |
Why?
|
| Isocoumarins | 1 | 2016 | 6 | 0.040 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 14289 | 0.040 |
Why?
|
| Motivation | 2 | 2018 | 499 | 0.040 |
Why?
|
| Coumarins | 1 | 2016 | 33 | 0.040 |
Why?
|
| Length of Stay | 3 | 2006 | 1900 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2019 | 597 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 11538 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2019 | 332 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 2027 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2010 | 901 | 0.030 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2016 | 50 | 0.030 |
Why?
|
| Renal Dialysis | 1 | 2003 | 945 | 0.030 |
Why?
|
| Medical Records | 1 | 1997 | 415 | 0.030 |
Why?
|
| Disease | 1 | 1997 | 165 | 0.030 |
Why?
|
| Geography | 1 | 2015 | 140 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 527 | 0.030 |
Why?
|
| Behavior | 1 | 2015 | 103 | 0.030 |
Why?
|
| Health Services | 1 | 1995 | 105 | 0.030 |
Why?
|
| Myocardial Revascularization | 1 | 1995 | 134 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 403 | 0.030 |
Why?
|
| Infection Control | 1 | 2016 | 270 | 0.030 |
Why?
|
| Cancer Pain | 1 | 2019 | 312 | 0.030 |
Why?
|
| Bias | 1 | 1995 | 205 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 1 | 2014 | 100 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2015 | 224 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 397 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 3578 | 0.030 |
Why?
|
| Pain Management | 1 | 2019 | 668 | 0.030 |
Why?
|
| Insurance, Health | 1 | 1995 | 250 | 0.030 |
Why?
|
| Catheter-Related Infections | 1 | 2016 | 270 | 0.030 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1995 | 314 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2016 | 450 | 0.030 |
Why?
|
| Family Planning Services | 1 | 1992 | 35 | 0.030 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2014 | 202 | 0.030 |
Why?
|
| APACHE | 3 | 1999 | 93 | 0.030 |
Why?
|
| Levonorgestrel | 1 | 1992 | 49 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 2170 | 0.030 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 4557 | 0.030 |
Why?
|
| Attitude | 1 | 1992 | 159 | 0.030 |
Why?
|
| Time and Motion Studies | 1 | 2011 | 43 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2006 | 1323 | 0.020 |
Why?
|
| Insurance Claim Reporting | 1 | 2010 | 17 | 0.020 |
Why?
|
| Coronary Disease | 1 | 1995 | 764 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2015 | 1944 | 0.020 |
Why?
|
| Patient Care | 1 | 2011 | 149 | 0.020 |
Why?
|
| Workflow | 1 | 2011 | 275 | 0.020 |
Why?
|
| Pulmonary Medicine | 1 | 2010 | 39 | 0.020 |
Why?
|
| Utilization Review | 1 | 2009 | 48 | 0.020 |
Why?
|
| Health Services Misuse | 1 | 2009 | 39 | 0.020 |
Why?
|
| Disease Progression | 2 | 2010 | 6682 | 0.020 |
Why?
|
| Serotonin Antagonists | 1 | 2008 | 41 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2011 | 749 | 0.020 |
Why?
|
| Asthma | 1 | 2016 | 871 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2009 | 495 | 0.020 |
Why?
|
| Emergency Medical Services | 1 | 2012 | 429 | 0.020 |
Why?
|
| Cisplatin | 1 | 2015 | 2432 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 827 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 756 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 698 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 1995 | 1011 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 1099 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 5687 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2019 | 8223 | 0.020 |
Why?
|
| Child | 2 | 2019 | 29154 | 0.020 |
Why?
|
| Observer Variation | 2 | 1999 | 671 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 1178 | 0.020 |
Why?
|
| Anti-Ulcer Agents | 1 | 2005 | 101 | 0.020 |
Why?
|
| Schizophrenia | 1 | 2008 | 369 | 0.020 |
Why?
|
| Liver Diseases | 1 | 2009 | 574 | 0.010 |
Why?
|
| Infant | 1 | 2019 | 13310 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2009 | 899 | 0.010 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2006 | 500 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 3472 | 0.010 |
Why?
|
| Prognosis | 2 | 2011 | 21713 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2019 | 16273 | 0.010 |
Why?
|
| Potassium | 1 | 2003 | 329 | 0.010 |
Why?
|
| Total Quality Management | 1 | 2001 | 34 | 0.010 |
Why?
|
| Intermittent Claudication | 1 | 2002 | 56 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 59536 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 4938 | 0.010 |
Why?
|
| Anxiety | 1 | 2008 | 1179 | 0.010 |
Why?
|
| Mass Screening | 1 | 2009 | 1509 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 4744 | 0.010 |
Why?
|
| Southwestern United States | 1 | 1999 | 62 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2009 | 3719 | 0.010 |
Why?
|
| Patient Selection | 1 | 2007 | 2055 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2002 | 552 | 0.010 |
Why?
|
| Medical History Taking | 1 | 1999 | 173 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 1999 | 980 | 0.010 |
Why?
|
| Medical Audit | 1 | 1997 | 188 | 0.010 |
Why?
|
| Facility Regulation and Control | 1 | 1995 | 3 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 1995 | 66 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2005 | 2403 | 0.010 |
Why?
|
| Kidney Failure, Chronic | 1 | 2003 | 960 | 0.010 |
Why?
|
| Cardiac Output, Low | 1 | 1995 | 81 | 0.010 |
Why?
|
| Medically Uninsured | 1 | 1995 | 102 | 0.010 |
Why?
|
| Delphi Technique | 1 | 1994 | 210 | 0.010 |
Why?
|
| Program Development | 1 | 1994 | 261 | 0.010 |
Why?
|
| Drug Implants | 1 | 1992 | 46 | 0.010 |
Why?
|
| Condoms | 1 | 1992 | 53 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 1992 | 208 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2006 | 5542 | 0.010 |
Why?
|
| Patient Care Team | 1 | 1994 | 795 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 4971 | 0.010 |
Why?
|